Alira Health

Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev

The firm’s partnership with industrial family investors, led by the Mulliez family investment arm, will accelerate growth and fuel the development of technology and solutions-enabled services.

News
Published on:
April 12, 2021

FRAMINGHAM, Mass. – April 12, 2021 – Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences , announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach.

Gabriele Brambilla

“I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advance the science and strategy of healthcare with our clients, ultimately enhancing patient outcomes.”

Benjamin Chambon

“We were looking for investors who would recognize the value of our mission, bring new perspectives to our approach, and partner with us for a long-term, ambitious plan of innovative and global growth. We are honored that Creadev, together with two other life sciences industrial families, chose to join Alira Health and support our leadership and vision“ said Benjamin Chambon, Chief Commercial Officer and Co-Founder of Alira Health.

 

“The Creadev team is proud to partner with Alira Health,” said Yohann Gbahoué, Executive Director, Creadev. “Alira Health’s approach to healthcare advisory is pioneering, and we see the impact of their work on patient outcomes growing as the company continues to implement their strategic vision. We join the entire investment team in congratulating Gabriele and the firm and look forward to supporting their future growth.”

The group of new investors will hold a minority interest in Alira Health. This operation empowers the company to accelerate the development of their technology-enabled services and boost the firm’s inorganic growth strategy in the U.S. and EU.

Advisors to Creadev: Finance & Tax (Alvarez & Marsal), Legal (King & Spalding), IT/Data (Z Consulting), HR (Selescope)

Advisors to Alira Health: Equiteq represented Alira Health in the transaction

About Creadev:
Creadev is an evergreen investment firm operating worldwide, controlled by the Mulliez family, founders of one of the largest Business to Consumer retail platforms in the world. Creadev is committed to long-term collaboration with innovative, passionate, and human-driven entrepreneurs that are focused on creating widespread access to essential goods and services such as healthcare, sustainable consumption and food. Based in Paris, and with offices in New-York, Shanghai and Nairobi, Creadev invests in companies well positioned to scale and become worldwide leaders in their respective sectors. Launched in 2002, Creadev has invested over €1.8 Bn in companies in stages ranging from venture to growth equity and buyout.

Read the press release on BusinessWire here.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris urna arcu, tempor ut laoreet eu, consectetur in mi. Maecenas rhoncus velit eget metus dignissim, sed bibendum elit lacinia. Mauris tristique, nisi ac sollicitudin dignissim, dui ipsum suscipit nulla, vitae sodales neque mauris vel est. Duis est velit, efficitur eget rutrum non, interdum et erat. Duis elit arcu, tristique quis feugiat quis, tincidunt tempus ligula. In hac habitasse platea dictumst. Ut dolor neque, egestas quis accumsan at, egestas sit amet leo.

Related news

Events April 1, 2025
The Medtech Forum 2025
Connect with our experts to learn how we can help accelerate patient access to your innovations.
EU HEOR MedTech Pricing
Case Studies March 20, 2025
Pharma Company Defines Advocacy Strategy Through Data-Driven Patient Association Mapping
Alira Health mapped 253 CVRM patient advocacy groups across 11 countries, delivering a data-driven strategy to optimize partnerships, advocacy efforts, and differentiation.
Patient Advocacy Patient Engagement Pharma
Articles March 17, 2025
Heart Failure Medical Devices Market Landscape in 2025
Explore the forces shaping heart failure medical devices, the emerging technologies driving innovation, and the key challenges on the road ahead.
Cardiology Medical Devices MedTech
Case Studies March 6, 2025
Rare Disease Pharma Maps Rare Cholestatic Liver Disease Journey for Targeted Patient Engagement
A global pharmaceutical company specializing in rare diseases, oncology, and neuroscience sought to analyze the patient journey for progressive familial intrahepatic cholestasis (PFIC).
Patient Centricity Pharma Rare Disease
Articles February 17, 2025
Rethinking Rare Disease Development: An Integrated, Patient Access-Driven Approach
Explore how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Patient Centricity Pharma Rare Disease
Events February 13, 2025
Medtech Summit Budapest 2025
Learn how can we help you optimize your regulatory strategy and navigate country-specific regulatory requirements.
EU MedTech
Articles February 11, 2025
From Diagnosis to Long-Term Care: Navigating the Rare Disease Journey
For Rare Disease Day, we spoke with patient engagement expert Luca Trentin on challenges faced by rare disease patients and how pharma can better understand their needs.
Patient Centricity Pharma Rare Disease
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.